XOMA Royalty CorpXOMAEarnings & Financial Report
XOMA Royalty Corp is a biopharmaceutical royalty investment and management firm that acquires and holds royalty interests in commercial-stage and late-clinical development therapeutic products. It partners with biotech and pharmaceutical companies worldwide, generating revenue from sales of approved medicines across key segments including oncology, immunology and rare diseases.
XOMA Q4 FY2025 Key Financial Metrics
Revenue
$1.1M
Gross Profit
N/A
Operating Profit
N/A
Net Profit
$6.1M
Gross Margin
N/A
Operating Margin
N/A
Net Margin
554.8%
YoY Growth
83.3%
EPS
$0.26
XOMA Royalty Corp Q4 FY2025 Financial Summary
XOMA Royalty Corp reported revenue of $1.1M (up 83.3% YoY) for Q4 FY2025, with a net profit of $6.1M (up 253.8% YoY) (554.8% margin).
Key Financial Metrics
| Total Revenue | $1.1M |
|---|---|
| Net Profit | $6.1M |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q4 FY2025 |
XOMA Royalty Corp Annual Revenue by Year
XOMA Royalty Corp annual revenue history includes year-by-year totals (for example, 2025 revenue was $10.3M).
XOMA Royalty Corp Quarterly Revenue & Net Profit History
XOMA Royalty Corp results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $1.1M | +83.3% | $6.1M | 554.8% |
| Q3 FY2025 | $225.0K | +800.0% | $14.1M | 6244.9% |
| Q2 FY2025 | $5.0M | +0.0% | $9.2M | 182.9% |
| Q1 FY2025 | $4.0M | +300.0% | $2.4M | 59.2% |
| Q4 FY2024 | $600.0K | -67.3% | N/A | N/A |
| Q3 FY2024 | $25.0K | -88.9% | $-17.2M | -68972.0% |
| Q2 FY2024 | $5.0M | +346.7% | $16.0M | 318.1% |
| Q1 FY2024 | $1.0M | +128.8% | $-8.6M | -859.5% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.0M | $5.0M | $25000 | $600000 | $4.0M | $5.0M | $225000 | $1.1M |
| YoY Growth | 128.8% | 346.7% | -88.9% | -67.3% | 300.0% | 0.0% | 800.0% | 83.3% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $219.4M | $243.3M | $223.3M | $221.3M | $212.8M | $223.5M | $263.2M | $272.7M |
| Liabilities | $137.1M | $143.3M | $138.5M | $139.4M | $128.1M | $131.0M | $155.2M | $168.7M |
| Equity | $82.3M | $100.0M | $84.8M | $61.9M | $84.6M | $72.4M | $87.9M | $83.9M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-4.9M | $2.7M | $-8.6M | $-13.7M | $2.2M | $6.5M | $-296000 | $-5.5M |